Tag: SCVS 2023

Initial case series indicates lithotripsy can help TCAR expand into high-risk...

Lithotripsy may hold the key to enabling more carotid artery disease patients who require calcification treatment to undergo stent placement via a transcarotid artery...

Tackling health insecurity ‘from the top down and the bottom up’

The feeling of being “uncertain, anxious and vulnerable” defines a creeping health insecurity problem riddling parts of the U.S. patient population—demographics who are underserved...

SCVS 2023: DAPT linked to better post-TCAR outcomes versus other drug...

Recent data presentations have revealed reduced risks of stroke and mortality among transcarotid artery revascularization (TCAR) patients who receive dual antiplatelet therapy (DAPT)—both preoperatively...

SCVS 2023: DAPT shows higher survival rate in patients with low...

A retrospective cohort study presented at the 2023 Society for Clinical Vascular Surgery (SCVS) Annual Symposium in Miami (March 25–29) has found lower-extremity bypass...

SCVS 2023: Endovascular-first or -only approach to all CLTI patients ‘is...

Michael S. Conte, MD, one of the foremost experts in the field of peripheral arterial disease (PAD), took attendees of the 2023 annual meeting...

SCVS 2023: Four decades of AAAs in the US: Rare epidemiological...

Abdominal aortic aneurysm (AAA) diagnosis and repair occurs among women almost 10 years later than in men—with similar age-adjusted mortality—the 2023 Society for Clinical...